Satya Das

February 16, 2023

Targeted therapy for neuroendocrine tumors

Cancer therapies that target VEGF receptor appear safe and effective for patients with pancreatic and non-pancreatic neuroendocrine tumors, meta-analysis of phase 2/3 clinical trials demonstrates.

By Kelsey Pinckard

January 19, 2022

Clinical score can guide PRRT therapy decisions for neuroendocrine tumors

A clinical score system developed by researchers at Vanderbilt-Ingram Cancer Center (VICC) has been validated that can guide peptide receptor radionuclide therapy treatment decisions.

By Tom Wilemon

November 2, 2021

Shifts in neuroendocrine cancer clinical trial design

Clinical trials that focus on specific types of neuroendocrine neoplasms — heterogeneous tumors that can occur anywhere in the body — will be more likely to enhance drug development for these tumors, Vanderbilt physicians assert.

By Leigh MacMillan

September 23, 2021

Clinical trial tests ATR inhibitor in difficult-to-treat cancers

By Doug Campbell

March 5, 2020

Das lands support for neuroendocrine tumor research

Satya Das, MD, has been awarded a $300,000 grant for a two-year period by the Neuroendocrine Tumor Research Foundation.

By Tom Wilemon